- Open
- 510.00
- High
- 529.65
- Low
- 510.00
- Close
- 518.00
- Change
- -10.00 (-1.90%)
- Volume
- 195,653
| 14 Aug 2026 | 10:48:27 | Admission to Trading |
| 11 Aug 2026 | 09:12:00 | Admission to Trading Application |
| 7 Aug 2026 | 07:00:06 | Half Year Trading Update and Notice of Results |
| 3 Aug 2026 | 07:00:04 | Total Voting Rights |
| 23 Jul 2026 | 14:21:31 | Holding(s) in Company |
| 30 Mar 2026 | Annual financial and audit reports | |
| 28 Apr 2025 | Annual financial and audit reports | |
| 30 Apr 2024 | Annual Report and accounts 31-Dec-2023 |
Oxford Biomedica plc operates as a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company focuses on the development and manufacturing of viral vectors, including lentivirus and adeno-associated virus (AAV), for pharmaceutical and biotechnology clients. Its services span from early-stage development to commercial production, supported by quality assurance and regulatory expertise. Oxford Biomedica has facilities in the UK, France, and the US, serving a global market with a growing demand for advanced therapeutic solutions.
| 14 Aug 2026 | 10:48:27 | Admission to Trading |
| 11 Aug 2026 | 09:12:00 | Admission to Trading Application |
| 7 Aug 2026 | 07:00:06 | Half Year Trading Update and Notice of Results |
| 3 Aug 2026 | 07:00:04 | Total Voting Rights |
| 23 Jul 2026 | 14:21:31 | Holding(s) in Company |
| 30 Mar 2026 | Annual financial and audit reports | |
| 28 Apr 2025 | Annual financial and audit reports | |
| 30 Apr 2024 | Annual Report and accounts 31-Dec-2023 |
Oxford Biomedica plc operates as a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company focuses on the development and manufacturing of viral vectors, including lentivirus and adeno-associated virus (AAV), for pharmaceutical and biotechnology clients. Its services span from early-stage development to commercial production, supported by quality assurance and regulatory expertise. Oxford Biomedica has facilities in the UK, France, and the US, serving a global market with a growing demand for advanced therapeutic solutions.
| Issuer | Mkt cap | 1Y |
|---|---|---|
OXBOXB | £627m | -0.1% |
| £618m | +0.4% | |
| £12m | +0.5% | |
| £12m | +1.8% | |
| £2m | -1.0% | |
| £381k | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
OXBOXB | £627m | -0.1% |
| £618m | +0.4% | |
| £12m | +0.5% | |
| £12m | +1.8% | |
| £2m | -1.0% | |
| £381k | -0.8% |